A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs GI 270384X (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 14 Jun 2007 New trial record.